Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

BACKGROUND: Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. METHODS: Be...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Pharmacol Toxicol
Prif Awduron: Olalla, Julián, Pérez-Stachowski, Javier, Tortajada, Begoña, Del Arco, Alfonso, Márquez, Efrén, De la Torre, Javier, Nieto, Miriam, García de Lomas, José María, Prada, José Luis, García-Alegría, Javier
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180504/
https://ncbi.nlm.nih.gov/pubmed/30305176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0252-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg